Gilson, C;
Chowdhury, S;
Parmar, MKB;
Sydes, MR;
STAMPEDE Investigators;
(2017)
Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform.
Clinical Oncology
, 29
(12)
pp. 778-786.
10.1016/j.clon.2017.10.004.
Preview |
Text
Gilson_1-s2.0-S0936655517304387-main.pdf - Published Version Download (441kB) | Preview |
Abstract
The treatment and outcomes for advanced prostate cancer have experienced significant progress over recent years. Importantly, the additional benefits of 'up front' chemotherapy (docetaxel) and abiraterone, over and above conventional androgen deprivation, have been separately demonstrated in the multi-arm, multi-stage (MAMS) STAMPEDE protocol, which continues recruitment to other questions. Alongside this, insights into the underlying molecular biology and, inevitably, the molecular heterogeneity of prostate cancer are opening the door to new therapeutic approaches. Incorporating this understanding and testing these hypotheses within STAMPEDE brings new challenges to the MAMS approach, but has the potential to further improve the outlook for this disease.
| Type: | Article |
|---|---|
| Title: | Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.clon.2017.10.004 |
| Publisher version: | https://doi.org/10.1016/j.clon.2017.10.004 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Biomarkers, clinical trial design, platform trials, precision medicine, prostate cancer |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10034975 |
Archive Staff Only
 |
View Item |
